Liminal BioSciences is a biopharmaceutical corporation providing advanced technologies for bio-separations and therapeutic products. It specializes in the discovery, development, and commercialization of novel small molecule compounds for respiratory, liver, and renal diseases. The company is particularly focused on creating solutions for rare and orphan diseases. Founded in 1992 and headquartered in Laval, Quebec, Liminal BioSciences has recently secured a $2.40M Post-IPO Equity investment on 16 July 2020, with funding coming from Amorchem and Genesys Partners. With its strong focus on addressing unmet medical needs in various therapeutic areas, Liminal BioSciences presents an attractive investment opportunity for venture capitalists in the biotechnology and health care industries. The company's dedication to developing innovative treatments for rare diseases further solidifies its potential for growth and impact in the pharmaceutical market.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $2.40M | 2 |
|
16 Jul 2020 |
| Post-IPO Equity | $37.14M | - | 24 Jun 2019 | |
| Post-IPO Equity | $9.50M | - | 07 Apr 2017 | |
| Private Equity Round | $60.14M | 7 |
|
25 May 2016 |
| Post-IPO Debt | $30.00M | 2 |
|
01 Mar 2016 |
No recent news or press coverage available for Liminal BioSciences.
We care about your data, and we'd love to use cookies make your experience better.
